About Substance-K receptor
Substance-K receptor (TACR2) is a protein
from Homo sapiens identified by UniProt accession
P21452, 398 residues long.
MolForge cross-references it against 0 known binders and
119 disease associations.
Target properties
| Protein name | Substance-K receptor |
| UniProt accession | P21452 |
| Gene | TACR2 |
| Organism | Homo sapiens |
| Length | 398 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (119)
Diseases linked to this target (Open Targets).
- depressive disorder · score 0.40
- neurodegenerative disease · score 0.36
- anxiety · score 0.35
- irritable bowel syndrome · score 0.35
- major depressive disorder · score 0.32
- ovarian cancer · score 0.26
- breast adenocarcinoma · score 0.25
- hemoglobin measurement · score 0.17
- head and neck squamous cell carcinoma · score 0.16
- erythrocyte count · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P21452-F1 | alphafold | PREDICTED | 79.77 | — |
Amino-acid sequence (398 residues)
MGTCDIVTEA NISSGPESNT TGITAFSMPS WQLALWATAY LALVLVAVTG NAIVIWIILA HRRMRTVTNY FIVNLALADL CMAAFNAAFN FVYASHNIWY FGRAFCYFQN LFPITAMFVS IYSMTAIAAD RYMAIVHPFQ PRLSAPSTKA VIAGIWLVAL ALASPQCFYS TVTMDQGATK CVVAWPEDSG GKTLLLYHLV VIALIYFLPL AVMFVAYSVI GLTLWRRAVP GHQAHGANLR HLQAMKKFVK TMVLVVLTFA ICWLPYHLYF ILGSFQEDIY CHKFIQQVYL ALFWLAMSST MYNPIIYCCL NHRFRSGFRL AFRCCPWVTP TKEDKLELTP TTSLSTRVNR CHTKETLFMA GDTAPSEATS GEAGRPQDGS GLWFGYGLLA PTKTHVEI
Explore Substance-K receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets